Clinical research suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could increase efficacy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback